Publications (194) ANTONIO RAFAEL ANTELA LOPEZ publications

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Cross-sectional analysis of a cohort of people over 65 years of age living with HIV

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 6, pp. 317-320

  3. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

2023

  1. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  2. Effects of frailty, geriatric syndromes, and comorbidity on mortality and quality of life in older adults with HIV

    BMC Geriatrics, Vol. 23, Núm. 1

2022

  1. Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: The FUNCFRAIL cohort study (GeSIDA 9817)

    PloS one, Vol. 17, Núm. 3, pp. e0266191

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges

    Infectious Diseases and Therapy, Vol. 11, Núm. 5, pp. 2017-2033

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  5. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir

    Drug design, development and therapy, Vol. 16, pp. 827-841

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

    AIDS (London, England), Vol. 35, Núm. 8, pp. 1283-1293

  3. Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

    PLoS ONE, Vol. 16, Núm. 4 April

  4. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

    BMC Health Services Research, Vol. 21, Núm. 1

  5. New horizons in the pharmaceutical care of HIV patients on long-term antiretroviral treatment

    Farmacia Hospitalaria

  6. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

  7. “I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

    Culture, Health and Sexuality, Vol. 23, Núm. 8, pp. 1066-1078

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

    AIDS and Behavior, Vol. 24, Núm. 12, pp. 3473-3481